Otsuka is a healthcare company dedicated to addressing complex medical needs through innovative research and development. Their focus spans various therapeutic areas, particularly in neuroscience and nephrology. In neuroscience, Otsuka has a long-standing commitment to developing treatments for mental health disorders, including schizophrenia, major depressive disorder, and other neuropsychiatric conditions. The company emphasizes the importance of clinical trials, which are essential for evaluating the safety and efficacy of new treatments, and actively seeks to include diverse populations in these studies to ensure equitable healthcare solutions.

In nephrology, Otsuka has made significant strides in advancing treatments for kidney diseases, notably through the development of first-in-class therapies for conditions like autosomal dominant polycystic kidney disease (ADPKD). Their approach combines rigorous scientific research with a commitment to patient advocacy, aiming to reshape treatment landscapes and address unmet medical needs. Otsuka's dedication to innovation is reflected in their ongoing investments in research and collaborations with other organizations, reinforcing their mission to improve health outcomes for patients and communities worldwide.

United States

There are two Otsuka pharmaceutical industry companies in the U.S.:

Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America.

Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis.

Otsuka

Company Details